A 12 week study to evaluate bioequivalence of ofatumumab injected by p
A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients
What was tested
Treatment tested
- Ofatumumab
B-lymphocyte antigen CD20 binding agent
Compared with
- Ofatumumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
AUC and Cmax calculated from data collected in the dosing interval after Week 8 dose administration in accordance with the assessment schedule.
How the body handles the medicine
Other measures (1)
- AUC
How the body handles the medicine
Papers
Results
Efficacy of the "PalliActive Caregivers" intervention for caregivers of patients with cancer in palliative care.BMC Palliat Care · 2025
Results
Effectiveness of Two Transcutaneous Electrical Nerve Stimulation (TENS) Protocols in Women with Provoked Vestibulodynia: A Randomized Controlled Trial.Med Sci (Basel) · 2023
Results
Audit and feedback with or without training in-practice targeting antibiotic prescribing (TiPTAP): a study protocol of a cluster randomised trial in dental primary care.Implement Sci · 2021
Results
Improving Cancer Patients' Insurance Choices (I Can PIC): A Randomized Trial of a Personalized Health Insurance Decision Aid.Oncologist · 2020
Results
Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study.Arthritis Res Ther · 2019
Results
Promoting Independence in Dementia (PRIDE): protocol for a feasibility randomised controlled trial.Trials · 2019
Results
Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial.Ital J Pediatr · 2017
Loading reviews and guidelines…
Related trials
- A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogeni
Phase 2 · Not yet recruiting
Still running
- Switch to Ofatumumab and Level of Immunoglobulins
Recruiting
Still running
- Non-interventional Study of Subcutaneous Ocrelizumab in Persons With R
Recruiting
Still running
- The HIt HArd and hiT Early in Multiple Sclerosis Trial
Phase 2 · Recruiting
Still running
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Mult
Recruiting
Still running
- Study to Assess Effects of Ublituximab in Pediatric Participants With
Phase 2 / Phase 3 · Recruiting
Still running
History
- In scope changed from true to false
Started
Aug 2018